Integrated NCD Intervention in Rural Nepal

June 22, 2021 updated by: Possible

An Integrated Intervention for Chronic Care Management in Rural Nepal: a Type 2 Hybrid Effectiveness-implementation Study

We will test an NCD intervention bundle incorporating the World Health Organisation (WHO)'s Package for Essential Non-Communicable Disease Interventions (PEN) within an approximate population of 300,000 people in rural Nepal. This intervention integrates three evidence-based approaches for both facility- and community-based NCD care focused on the key areas of Clinical Practice, Counseling, and Technology for two tiers of non-physician healthcare worker - Mid-Level Providers and Community Health Workers: 1) Task-shifting of evidence-based medicine algorithms and clinical skills from PEN protocols to non-physician healthcare workers; 2) Delivering quality counseling based on the Motivational Interviewing Model to drive behavior change with respect to both treatment adherence (defined as medication adherence and follow-up completion) and risk factor modification (alcohol, tobacco, diet, physical activity); 3) Employing a facility- and community-based clinical decision support tool for effective integration of PEN protocols into non-physician healthcare worker workflow. This five-year study will initial test the acceptability and feasibility of the intervention (two years) followed by a type 2 hybrid effectiveness-implementation research trial (three years) to which we will apply the RE-AIM implementation evaluative framework of both outcomes and process indicators. Co-primary outcomes for the intervention bundle will be: a) disease-specific, evidence-based control metrics that measures clinical efficacy; b) qualitative evaluation of acceptability and feasibility that incorporates perspectives of patients, providers, and government stakeholders; and c) an implementation checklist of key intervention process measures.

Study Overview

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Achham/Province 7
      • Sanfebagar-10, Achham/Province 7, Nepal
        • Bayalpata Hospital
    • Dolakha/Province 3
      • Charikot, Dolakha/Province 3, Nepal
        • Charikot Primary Health Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Adult patients aged 18 or older that screen into Nyaya Health Nepal/Possible's chronic disease program for the following conditions: Hypertension, Type II Diabetes Mellitus, COPD, and Asthma OR
  2. Adult patients aged 18 or older with end-organ pathology resulting from the aforementioned conditions including the following: Chronic Kidney Disease, Ischemic Heart Disease, Cerebrovascular Disease AND
  3. Healthcare staff; mid-level providers serving at district/primary health center-level facility; community health workers serving village clusters, Nyaya Health Nepal/Possible and Government of Nepal/Ministry of Health and Population employees involved in study design, program implementation, data collection, or data analysis processes.

    • Note, study populations 1 and 2 must reside in either Achham or Dolakha (Nepal) districts.

      • Patients must have a noncommunicable note in electronic medical record system at least twice (indicating at least one follow-up visit) and must have minimum 12 weeks in between baseline/endline clinical measures (indicating patients have been followed up for at least 3 months and have 3 months of exposure to intervention).

        • Patients do not need to have been in study for all 3 years. Duration of exposure to intervention will depend on stepped implementation design.

Patients may be identified at Bayalpata Hospital (Achham, Nepal) or Charikot Primary Health Center (Dolakha, Nepal) by facility clinicians. Community health workers can also identify hypertensive patients and refer them to the facility for diagnosis confirmation. Patient enrollment will not be restricted by economic status or caste. Patients will not be recruited exclusively to participate in the study but will undergo routine evaluations, entering the final diagnosis in electronic health record system, tracking progress at each patient contact, the frequency for which is determined by the clinician's recommendation per World Health Organization Package of Essential Noncommunicable disease intervention protocols and the patient's availability. Patients will receive longitudinal care via the community health workers at their homes and at the hospitals by mid-level providers and staff physicians. Their receipt of care is not contingent upon their enrollment in the study; they receive care per routine service delivery.

Exclusion Criteria:

  1. Patients migrate from the study are before completion of any of the Package of Essential Noncommunicable disease interventions
  2. Patients explicitly request exclusion from the study and decline to consent to the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: HEALTH_SERVICES_RESEARCH
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Bundled NCD WHO PEN Intervention
Mixed-methods type 2 hybrid effectiveness-implementation study to evaluate an integrated NCD care management intervention
In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population. In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Type II diabetes mellitus control measure
Time Frame: 24 months
Percentage of enrolled type II diabetes patients achieving "at goal" status, at the completion of the study period (type II diabetes mellitus: Hemoglobin A1c < 7.5 OR fasting blood sugar <130 mg/dL)
24 months
Hypertension control measure
Time Frame: 24 months
Percentage of enrolled hypertension patients achieving "at goal" status, at the completion of the study period (hypertension: blood pressure <130/80mm Hg or patient-tailored goal per risk stratification)
24 months
COPD control measure
Time Frame: 24 months
Percentage of enrolled COPD patients achieving "at goal" status, at the completion of the study period (COPD: exacerbation status ≤1/3 Anthonisen criteria)
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tobacco use
Time Frame: 24 months
Percentage of enrolled NCD patients who were using tobacco at enrollment who are non-users or who have reduced by >50% their tobacco intake, at the completion of the study period
24 months
Alcohol use
Time Frame: 24 months
Percentage of enrolled NCD patients who were alcohol drinkers at enrollment who are non-drinkers or who have reduced by >50% alcohol intake, at the completion of the study period
24 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Home visit coverage (Reach)
Time Frame: 1 month
Percentage of enrolled NCD patients having a CHW home visit
1 month
Clinic visit coverage (Reach)
Time Frame: 1 month
Percentage of enrolled NCD patients having an MLP visit at the clinic, measured monthly according to the patients indicated to be seen that month based on protocol-based guidelines
1 month
Demographic, geographic barriers and facilitators
Time Frame: 24 months
Percentage of enrolled NCD patients whose CHW has GPS-mapped their households, describing barriers/facilitators to individuals' access, and identifying contributors to variation/inequities
24 months
Loss to follow-up (Reach)
Time Frame: 24 months
Percentage of patients, stratified by demographic data and NCD conditions, that are lost-to-follow-up after enrollment
24 months
Monthly patient touch-points (Effectiveness)
Time Frame: 1 month
Number of monthly per-patient touch-points, including interactions by both MLPs and CHWs
1 month
Evidence-based hypertension management (Effectiveness)
Time Frame: 3 months
Percentage of enrolled hypertension patients in accordance with evidence-based recommendations, as prescribed by clinical algorithms, assessed quarterly by EHR audits
3 months
Evidence-based diabetes management (Effectiveness)
Time Frame: 3 months
Percentage of enrolled diabetes patients in accordance with evidence-based recommendations, as prescribed by clinical algorithms, assessed quarterly by EHR audits
3 months
Evidence-based COPD management (Effectiveness)
Time Frame: 3 months
Percentage of enrolled COPD patients in accordance with evidence-based recommendations, as prescribed by clinical algorithms, assessed quarterly by EHR audits
3 months
Village cluster adoption (Adoption)
Time Frame: 24 months
Percentage of intended village clusters receiving intervention
24 months
Timely adoption (Adoption)
Time Frame: 24 months
Percentage of intended village clusters rolling-out intervention within 3 months of schedule, according to local governance decisions to roll-out the intervention
24 months
CHW training adoption (Adoption)
Time Frame: 6 months
Percentage of CHWs trained in intervention implementation within first six months
6 months
CHW retention adoption (Adoption)
Time Frame: 24 months
Percentage of of trained CHWs retained in their positions at the completion of the study period
24 months
MLP training adoption (Adoption)
Time Frame: 24 months
Percentage of MLPs trained in intervention implementation
24 months
MLP retention adoption (Adoption)
Time Frame: 24 months
Percentage of of trained MLPs retained in their positions at the completion of the study period
24 months
Care integration (Implementation)
Time Frame: 1 month
Percentage of all NCD patients enrolled at the facilities seen by CHWs at home within first month
1 month
CHW supervision completion (Implementation)
Time Frame: 3 months
Percentage of scheduled CHW supervision field visits completed, stratified by CHN and district
3 months
CHW supervision review meeting completion (Implementation)
Time Frame: 3 months
Percentage of scheduled quarterly data review meetings held with CHWs and CHNs
3 months
CHW home visit completion (Implementation)
Time Frame: 3 months
Percentage of enrolled NCD patients with 100% of algorithm-indicated home visits received
3 months
CHW home visit fidelity (Implementation)
Time Frame: 3 months
Percentage of of topics included at each session as dictated by the condition-specific algorithms, assessed during the CHW supervision field visits by CHNs
3 months
Referral fidelity (Implementation)
Time Frame: 3 months
Percentage of patients appropriately referred to MLP care as indicated by the clinical algorithms, assessed during the CHW supervision field visits by CHNs
3 months
Referral completion (Implementation)
Time Frame: 3 months
Percentage of % of patients referred by CHWs seen by MLPs within the prescribed time window according to the clinical algorithms (e.g. 24hours, 72 hours, 1 week)
3 months
MLP supervision model (Implementation)
Time Frame: 3 months
Percentage of enrolled NCD patients appropriately referred to see a physician by MLPs as indicated by the clinical algorithms, assessed during monthly physician supervision sessions
3 months
MLP visit fidelity (Implementation)
Time Frame: 1 month
Percentage of of enrolled NCD patients with 100% of algorithm-indicated facility visits received, assessed during monthly physician supervision sessions
1 month
Total intervention cost (Maintenance)
Time Frame: 24 months
Cost of each intervention component and total costs using the Joint Learning Network costing methodology
24 months
Intervention initiation costs (Maintenance)
Time Frame: 24 months
Percentage breakdown of initial (one-time) costs for intervention (training, equipment, etc)
24 months
Intervention maintenance costs (Maintenance)
Time Frame: 24 months
Percentage breakdown of maintenance (recurring) costs (on-going training, personnel, materials, and other)
24 months
Facility vs. community costs (Maintenance)
Time Frame: 24 months
Percentage of costs of health care divided between facility level and community level
24 months
Geographic cost variation (Maintenance)
Time Frame: 24 months
Variance in costs between village clusters and districts within the intervention catchment area
24 months
Out-of-pocket patient costs (Maintenance)
Time Frame: 24 months
Percentage of costs of health care divided between facility level and community level
24 months
Integrated intervention cost-effectiveness analysis (Maintenance)
Time Frame: 24 months
Pre/post intervention marginal effectiveness for primary outcomes
24 months
Cost per unit patient (Maintenance)
Time Frame: 24 months
Intervention cost per enrolled patient
24 months
Cost per capita (Maintenance)
Time Frame: 24 months
Intervention cost per capita
24 months
Projected scale cost(Maintenance)
Time Frame: 24 months
Projected cost to scale intervention nationally
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Sabitri Sapkota, PhD, MPH, Possible/Nyaya Health Nepal

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

December 1, 2019

Primary Completion (ANTICIPATED)

March 1, 2023

Study Completion (ANTICIPATED)

December 1, 2023

Study Registration Dates

First Submitted

September 6, 2019

First Submitted That Met QC Criteria

September 10, 2019

First Posted (ACTUAL)

September 12, 2019

Study Record Updates

Last Update Posted (ACTUAL)

June 25, 2021

Last Update Submitted That Met QC Criteria

June 22, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on Bundled NCD WHO PEN Intervention

Subscribe